Zhehai Wang

发表

Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial.

Ying Cheng, Jianming Xu, M. Tao, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tislelizumab Plus Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (RATIONALE 304): A Randomized Phase 3 Trial.

Yunpeng Liu, Dong Wang, Jie Wang, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

PDL1 high expression without TP53, KEAP1 and EPHA5 mutations could better predict survival for patients with NSCLC receiving atezolizumab.

Xiao Han, Haiyong Wang, Zhehai Wang, 2020, Lung cancer.

Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy

Ying Cheng, Jianxing He, R. Guo, 2020, Clinical Cancer Research.

Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial.

Ying Cheng, Jian-hua Chang, Yunpeng Liu, 2020, The Lancet. Respiratory medicine.

中国非小细胞肺癌免疫检查点抑制剂治疗专家共识（2019年版）

D. Lin, B. Han, Baocheng Wang, 2020, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

培美曲塞联合顺铂对比吉西他滨联合顺铂一线治疗晚期非鳞非小细胞肺癌的随机、对照、多中心临床研究

Baolan Li, Li Zhang, Jian-hua Chang, 2012, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Clinical significance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancer

Minmin Li, Zhehai Wang, Jun Guo, 2014, OncoTargets and therapy.

Oncotargets and Therapy Dovepress Clinical Significance of Ugt1a1 Gene Polymorphisms on Irinotecan-based Regimens as the Treatment in Metastatic Colorectal Cancer

Minmin Li, Zhehai Wang, Jun Guo, 2022 .

[Efficacy and toxicity of pemetrexed or gemcitabine combined with cisplatin in the treatment of patients with advanced non-small cell lung cancer].

Cheng Huang, Shucai Zhang, S. Jiao, 2012, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Association of chemotherapy-induced leucopenia with treatment outcomes in advanced non-small-cell lung cancer cases receiving the NP regimen.

Zhehai Wang, Jun Guo, Jie Liu, 2012, Asian Pacific journal of cancer prevention : APJCP.

Clinical study of docetaxel-vinorelbine as second-line chemotherapy in advanced non-small cell lung cancer

Zhehai Wang, Jun Guo, Jie Liu, 2008 .

The efficacy of anlotinib as third-line treatment for non-small cell lung cancer by EGFR mutation status: a subgroup analysis of the ALTER0303 randomized phase 3 study

F. Tanaka, K. Nan, Baolan Li, 2021, Translational lung cancer research.

Greater efficacy of chemotherapy plus bevacizumab compared to chemo- and targeted therapy alone on non-small cell lung cancer patients with brain metastasis

Qianqian Zhang, Zhehai Wang, Jun Guo, 2015, Oncotarget.

Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment

Ying Cheng, K. Nan, Baolan Li, 2018, Cancer biology & medicine.

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.

Ying Cheng, Y. Ba, Jianming Xu, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumour Necrosis Factor-α Gene Polymorphism Is Associated with Metastasis in Patients with Triple Negative Breast Cancer

Kan Zhai, Zhehai Wang, Hui-hui Li, 2015, Scientific Reports.

Cutaneous metastasis from pancreatic cancer: A case report and systematic review of the literature

Zhehai Wang, Shu Zhang, H. Zhou, 2014, Oncology letters.

AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations

Xiaoping Zhou, V. Miller, Siraj M. Ali, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study.

Gong-yan Chen, Yun-peng Yang, Zhehai Wang, 2022, Lung cancer.

Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients

Y. Wang, Xiao Han, Zhehai Wang, 2016, Drug design, development and therapy.

Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer: a prospective, single-arm, phase II study in China

Xiangjiao Meng, Yulan Sun, S. Yuan, 2022, Journal of Cancer Research and Clinical Oncology.

The efficacy and safety of immunotherapy in thymic epithelial tumors: more effective, more risky: a systematic review

Caicun Zhou, Xinyu Song, Yayi He, 2021, Journal of thoracic disease.

Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non‐small‐cell lung cancer characterizes the features of response to PD‐1 blockade plus chemotherapy

Tao Zhang, Wei Shi, Jian-hua Chang, 2022, Cancer communications.

Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous non-small-cell lung cancer: results from a randomized, double-blind, phase 3 trial (ORIENT-12).

Baolan Li, Chengping Hu, P. Sun, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Management of anlotinib‐related adverse events in patients with advanced non‐small cell lung cancer: Experiences in ALTER‐0303

Ying Cheng, B. Han, K. Nan, 2019, Thoracic cancer.

Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial

Ying Cheng, R. Pirker, K. Nan, 2018, JAMA oncology.

Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)

Ying Cheng, B. Han, Baolan Li, 2018, British Journal of Cancer.

Efficacy and safety of third-line treatment with anlotinib in patients with refractory advanced non-small-cell lung cancer (ALTER-0303): a randomised, double-blind, placebo-controlled phase 3 study

B. Han, K. Nan, Jianxing He, 2017 .

Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis from a single-arm, phase 2 trial

Xiangjiao Meng, Yulan Sun, Zhong-tang Wang, 2022, Journal for ImmunoTherapy of Cancer.

Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects

Zhehai Wang, Meili Sun, Huan Shi, 2014, Molecular Cancer.

Improving the efficacy and safety of engineered T cell therapy for cancer.

Zhehai Wang, Huan Shi, Lin Liu, 2013, Cancer letters.

Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Non-squamous NSCLC in the Phase III ORIENT-11 Study.

Baolan Li, Wei-min Li, B. Peng, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Tuberculosis infection and lung adenocarcinoma: Mendelian randomization and pathway analysis of genome-wide association study data from never-smoking Asian women.

X. Hua, Jianxin Shi, Y. Miyagi, 2019, Genomics.

Association between GWAS-identified lung adenocarcinoma susceptibility loci and EGFR mutations in never-smoking Asian women, and comparison with findings from Western populations

Ping Wang, Junjie Wu, Jian Su, 2016, Human molecular genetics.

Meta-analysis of genome-wide association studies identifies multiple lung cancer susceptibility loci in never-smoking Asian women.

Hongbing Shen, Chien-Jen Chen, N. Rothman, 2016, Human molecular genetics.

CTLA-4 +49A>G Polymorphism Is Associated with Advanced Non-Small Cell Lung Cancer Prognosis

Xianrang Song, Jinxiang Han, B. Song, 2011, Respiration.

EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer

Zhehai Wang, S. Fang, 2014, Drug design, development and therapy.

Relationship between tumor size and metastatic site in patients with stage IV non-small cell lung cancer: A large SEER-based study

Xiao Han, Haiyong Wang, Zhehai Wang, 2019, PeerJ.

Duration of immunotherapy in patients with advanced lung adenocarcinoma with negative driver genes: case report and literature review

Xiao Han, Haiyong Wang, Zhehai Wang, 2020, Thoracic cancer.

Total lymphocyte count, neutrophil–lymphocyte ratio, and platelet–lymphocyte ratio as prognostic factors in advanced non–small cell lung cancer with chemoradiotherapy

Dawei Chen, Xinyu Song, Haiyong Wang, 2018, Cancer management and research.

Occurrence of hypertension during third‐line anlotinib is associated with progression‐free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trial

Ying Cheng, B. Han, K. Nan, 2021, Thoracic cancer.

Comparison of bevacizumab plus chemotherapy with chemotherapy alone in advanced non-small-lung cancer patients

Zhehai Wang, N. Tang, 2016, OncoTargets and therapy.

Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous non-small cell lung cancer: a randomized, double-blind, phase 3 study (ORIENT-11).

Ying Cheng, B. Han, Baolan Li, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Spatial multi-omics revealed the impact of tumor ecosystem heterogeneity on immunotherapy efficacy in patients with advanced non-small cell lung cancer treated with bispecific antibody

Haitao Luo, Xiaoshen Zhang, T. Jiang, 2023, Journal for ImmunoTherapy of Cancer.

Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenografts

Shu Fang, Qianqian Zhang, Xiao Han, 2016, Oncotarget.

Comparison of single-agent chemotherapy and targeted therapy to first-line treatment in patients aged 80 years and older with advanced non-small-cell lung cancer

Qianqian Zhang, Xiao Han, Minmin Li, 2015, OncoTargets and therapy.

Selection of chemotherapy for non-small cell lung cancer is facilitated by new therapeutic strategies.

Zhehai Wang, 2014, International journal of clinical and experimental medicine.

Review Article Selection of chemotherapy for non-small cell lung cancer is facilitated by new therapeutic strategies

Zhehai Wang, 2014 .

Association of genetic polymorphisms in the interleukin-10 promoter with risk of prostate cancer in Chinese

B. Song, Jialin Wang, Zhehai Wang, 2010, BMC Cancer.

DNA repair gene XRCC1 polymorphisms and non-Hodgkin lymphoma risk in a Chinese population.

Xianrang Song, Jinxiang Han, B. Song, 2009, Cancer genetics and cytogenetics.

Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer

C. Bai, B. Han, Qiang Li, 2018, Investigational New Drugs.

Molecular subtyping of small‐cell lung cancer based on mutational signatures with different genomic features and therapeutic strategies

Shuangxiu Wu, Zhenxiang Li, Chenyue Zhang, 2022, Cancer science.

Polymorphisms of interleukin-10 promoter are not associated with prognosis of advanced gastric cancer.

B. Song, Jia‐Lin Wang, Zhehai Wang, 2011, World journal of gastroenterology.

Mechanisms of Gefitinib-mediated reversal of tamoxifen resistance in MCF-7 breast cancer cells by inducing ERα re-expression

Yang Zhang, B. Song, Minmin Li, 2015, Scientific Reports.

PLNR≤20% may be a benefit from PORT for patients with IIIA-N2 NSCLC: a large population-based study

Zhenxiang Li, Jiamao Lin, Haiyong Wang, 2018, Cancer management and research.

Characteristics and survival difference of clinical tumor size 0 extensive-stage small cell lung cancer with different metastasis pattern.

Xiao Han, Haiyong Wang, Zhehai Wang, 2018, Journal of thoracic disease.

中国非小细胞肺癌免疫检查点抑制剂治疗专家共识（2020年版）

Jingjing Liu, Ying Cheng, B. Han, 2021, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer: a prospective, single-arm, phase II study in China

Xiangjiao Meng, Yulan Sun, S. Yuan, 2022, Journal of Cancer Research and Clinical Oncology.

Adoptive T-cell therapy of B-cell malignancies: conventional and physiological chimeric antigen receptors.

Zhehai Wang, Meili Sun, Lin Liu, 2012, Cancer letters.

The status of immunosuppression in patients with stage IIIB or IV non-small-cell lung cancer correlates with the clinical characteristics and response to chemotherapy

Y. Wang, Zhehai Wang, Guo-fang Hu, 2017, OncoTargets and therapy.

A current review of folate receptor alpha as a potential tumor target in non-small-cell lung cancer

Zhehai Wang, Jun Guo, Huan Shi, 2015, Drug design, development and therapy.

The genetic polymorphisms of intercellular cell adhesion molecules and breast cancer susceptibility: a meta-analysis

Zhehai Wang, Meili Sun, Lin Liu, 2012, Molecular Biology Reports.

A new nomogram and risk classification system for predicting survival in small cell lung cancer patients diagnosed with brain metastasis: a large population-based study

Xiao Han, Haiyong Wang, Zhehai Wang, 2021, BMC cancer.

Effect of anlotinib as a third‐ or further‐line therapy in advanced non‐small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial

Jing Zhu, Ying Cheng, B. Han, 2020, Cancer medicine.

CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial

Ying Cheng, Jianming Xu, Yunpeng Liu, 2019, Cancer communications.

Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study

N. Xu, Ying Cheng, P. Lagiou, 2017, Journal of Hematology & Oncology.

Surgical intervention may be a therapeutic option for NSCLC patients with AJCC stage IV: a large population-based study

Haiyong Wang, Zhehai Wang, Cheng Li, 2018, Cancer management and research.

Tumor Primary Location May Affect Metastasis Pattern for Patients with Stage IV NSCLC: A Population-Based Study

Xiao Han, Zhenxiang Li, Jiamao Lin, 2020, Journal of oncology.

Less immune cell infiltration and worse prognosis after immunotherapy for patients with lung adenocarcinoma who harbored STK11 mutation.

Haiyong Wang, Zhehai Wang, Jun Guo, 2020, International immunopharmacology.

Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: A real-world study in a Chinese population

Xiao Han, Zhehai Wang, Minglei Wang, 2023, Frontiers in Oncology.

Efficacy of Aumolertinib (HS-10296) in Patients with Advanced EGFR T790M+ NSCLC: Updated Post NMPA-approval Results from the APOLLO Registrational Trial.

Ping Wang, Ying Cheng, C. Chiu, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Genome-wide association study of lung adenocarcinoma in East Asia and comparison with a European population

L. Kiemeney, Y. Miyagi, B. Qian, 2023, Nature communications.

Correlation between EGFR mutation status and response to first-line platinum-based chemotherapy in patients with advanced non-small cell lung cancer

Minmin Li, Zhehai Wang, Jun Guo, 2014, OncoTargets and therapy.

SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer

D. Day, Lifeng Wang, H. Pan, 2023, Journal for ImmunoTherapy of Cancer.

Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial

He-long Zhang, Yunpeng Liu, Yanqiu Zhao, 2022, Signal Transduction and Targeted Therapy.

Abstract LB512: RATIONALE-304: The association of tumor mutational burden (TMB) with clinical outcomes of tislelizumab (TIS) + chemotherapy (chemo) versus chemo alone as first-line treatment for advanced non-squamous non-small cell lung cancer (nsq-NSCLC)

Yangguang Shi, Zhirong Shen, Yan Yu, 2022, Cancer Research.

Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis

Y. Wang, Qianqian Zhang, Xiao Han, 2016, Drug design, development and therapy.